Evidence map›Paper›PMID 39190087›Full record

ReviewMolecular diagnosis & therapy2024

Unlocking the Complexity: Exploration of Acute Lymphoblastic Leukemia at the Single Cell Level.

Margo Aertgeerts, Sarah Meyers, Sofie Demeyer, Heidi Segers, Jan Cools

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular diagnosis & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Margo AertgeertsDepartment of Oncology, KU Leuven, Leuven, Belgium.ORCID 0000-0003-0734-380X
Sarah MeyersDepartment of Human Genetics, KU Leuven, Leuven, Belgium.ORCID 0000-0002-9592-8850
Sofie DemeyerDepartment of Human Genetics, KU Leuven, Leuven, Belgium.ORCID 0000-0002-8193-5734
Heidi SegersDepartment of Oncology, KU Leuven, Leuven, Belgium. heidi.segers@uzleuven.be.ORCID 0000-0002-3604-7850
Jan CoolsDepartment of Human Genetics, KU Leuven, Leuven, Belgium. jan.cools@kuleuven.be.ORCID 0000-0001-6626-5843

Funding

KU Leuven C14/18/104Stichting Tegen Kanker Clinical Mandates 2023
6 · The paper itself

Abstract

Acute lymphoblastic leukemia (ALL) is the most common cancer in children. ALL originates from precursor lymphocytes that acquire multiple genomic changes over time, including chromosomal rearrangements and point mutations. While a large variety of genomic defects was identified and characterized in ALL over the past 30 years, it was only in recent years that the clonal heterogeneity was recognized. Thanks to the latest advancements in single-cell sequencing techniques, which have evolved from the analysis of a few hundred cells to the analysis of thousands of cells simultaneously, the study of tumor heterogeneity now becomes possible. Different modalities can be explored at the single-cell level: DNA, RNA, epigenetic modifications, and intracellular and cell surface proteins. In this review, we describe these techniques and highlight their advantages and limitations in the study of ALL biology. Moreover, multiomics technologies and the incorporation of the spatial dimension can provide insight into intercellular communication. We describe how the different single-cell sequencing technologies help to unravel the molecular complexity of ALL, shedding light on its development, its heterogeneity, its interaction with the leukemia microenvironment and possible relapse mechanisms.

Indexed as

Precursor Cell Lymphoblastic Leukemia-LymphomaSingle-Cell AnalysisEpigenesis, GeneticGenetic HeterogeneityHigh-Throughput Nucleotide SequencingHumansTumor Microenvironment

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.